Strategies, design, and chemistry in siRNA delivery systems

Yizhou Dong, Daniel J. Siegwart, Daniel G. Anderson

Research output: Contribution to journalReview articlepeer-review

242 Scopus citations


Emerging therapeutics that utilize RNA interference (RNAi) have the potential to treat broad classes of diseases due to their ability to reversibly silence target genes. In August 2018, the FDA approved the first siRNA therapeutic, called ONPATTRO™ (Patisiran), for the treatment of transthyretin-mediated amyloidosis. This was an important milestone for the field of siRNA delivery that opens the door for additional siRNA drugs. Currently, >20 small interfering RNA (siRNA)-based therapies are in clinical trials for a wide variety of diseases including cancers, genetic disorders, and viral infections. To maximize therapeutic benefits of siRNA-based drugs, a number of chemical strategies have been applied to address issues associated with efficacy, specificity, and safety. This review focuses on the chemical perspectives behind non-viral siRNA delivery systems, including siRNA synthesis, siRNA conjugates, and nanoparticle delivery using nucleotides, lipids, and polymers. Tracing and understanding the chemical development of strategies to make siRNAs into drugs is important to guide development of additional clinical candidates and enable prolonged success of siRNA therapeutics.

Original languageEnglish (US)
Pages (from-to)133-147
Number of pages15
JournalAdvanced Drug Delivery Reviews
StatePublished - Apr 2019


  • Nanomaterials
  • Therapeutics
  • siRNA

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Strategies, design, and chemistry in siRNA delivery systems'. Together they form a unique fingerprint.

Cite this